

Income statement

Three months ended 30th June 2009

	Total Q2 2009 £m	Total Q2 2008 £m	Growth	
			CER%	£%
TURNOVER	6,747	5,874	(2)	15
Cost of sales	(1,692)	(1,513)	1	12
Gross profit	5,055	4,361	(3)	16
Selling, general and administration	(2,292)	(1,796)	4	28
Research and development	(973)	(820)	4	19
Other operating income	405	194		
OPERATING PROFIT	2,195	1,939	(5)	13
Finance income	18	96		
Finance expense	(168)	(214)		
Share of after tax profits of associates and joint ventures	17	15		
PROFIT BEFORE TAXATION	2,062	1,836	(6)	12
Taxation	(601)	(529)		
<i>Tax rate %</i>	29.1%	28.8%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,461	1,307	(7)	12
Profit attributable to minority interests	26	21		
Profit attributable to shareholders	1,435	1,286		
	1,461	1,307		
EARNINGS PER SHARE	28.3p	24.6p	(4)	15
Diluted earnings per share	28.3p	24.4p		

Pharmaceuticals turnover

Three months ended 30th June 2009

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	1,734	6	25	825	5	34	550	2	11	359	16	33
<i>Avamys/Veramyst</i>	47	>100	>100	18	7	29	16	>100	>100	13	>100	>100
<i>Flixonase/Flonase</i>	39	(46)	(40)	8	(82)	(76)	12	(25)	(25)	19	6	19
<i>Flixotide/Flovent</i>	189	1	20	97	12	43	43	(5)	-	49	(11)	4
<i>Seretide/Advair</i>	1,245	9	29	648	7	37	401	3	13	196	27	45
<i>Serevent</i>	59	(21)	(11)	18	(13)	13	29	(18)	(15)	12	(38)	(25)
<i>Ventolin</i>	112	23	40	32	>100	>100	36	3	9	44	(3)	10
<i>Zyrtec</i>	17	63	>100	-	-	-	-	-	-	17	63	>100
Anti-virals	952	5	27	496	10	40	236	(2)	8	220	5	24
HIV	382	(10)	6	164	(8)	15	156	(14)	(5)	62	(5)	13
<i>Agenerase, Lexiva</i>	43	(8)	13	23	6	28	16	(13)	-	4	(50)	-
<i>Combivir</i>	102	(17)	(2)	44	(15)	7	37	(25)	(16)	21	(5)	11
<i>Epivir</i>	31	(24)	(9)	11	(18)	-	12	(33)	(20)	8	(13)	-
<i>Epizcom/Kivexa</i>	129	6	24	50	-	28	59	-	9	20	55	82
<i>Trizivir</i>	48	(18)	(4)	25	(13)	9	20	(25)	(17)	3	-	-
<i>Ziagen</i>	25	(19)	(4)	11	(18)	-	9	(20)	(10)	5	(20)	-
<i>Valtrex</i>	379	9	37	291	16	49	39	(3)	8	49	(15)	7
<i>Relenza</i>	60	>100	>100	19	>100	>100	25	>100	>100	16	-	-
<i>Zeffix</i>	55	(4)	17	5	(25)	25	8	17	33	42	(5)	14
Central nervous system	449	(53)	(45)	142	(79)	(74)	144	(8)	1	163	4	27
<i>Imigran/Imitrex</i>	68	(65)	(61)	33	(79)	(76)	23	(13)	(4)	12	-	20
<i>Lamictal</i>	103	(73)	(68)	45	(86)	(83)	38	(8)	-	20	(6)	18
<i>Requip</i>	51	(22)	(12)	6	(78)	(67)	35	3	13	10	-	11
<i>Requip XL</i>	30	>100	>100	8	-	-	22	>100	>100	-	-	-
<i>Seroxat/Paxil</i>	138	(13)	9	13	(31)	(19)	27	(19)	(13)	98	(8)	23
<i>Treximet</i>	12	25	50	12	25	50	-	-	-	-	-	-
<i>Wellbutrin, Wellbutrin XL</i>	30	(72)	(69)	20	(81)	(78)	7	100	>100	3	(20)	(40)
Cardiovascular and urogenital	580	10	33	360	12	43	145	2	12	75	19	39
<i>Arixtra</i>	61	39	69	33	63	>100	23	24	35	5	-	67
<i>Avodart</i>	134	21	46	83	16	51	37	21	32	14	44	56
<i>Coreg, Coreg CR</i>	51	(9)	16	50	(7)	16	-	-	-	1	(100)	-
<i>Fraxiparine</i>	58	(9)	-	-	-	-	43	(15)	(7)	15	17	25
<i>Levitra</i>	18	8	38	17	-	31	1	-	-	-	-	-
<i>Lovaza</i>	104	22	55	104	24	58	-	-	-	-	-	-
<i>Vesicare</i>	26	31	63	26	31	63	-	-	-	-	-	-
<i>Volibris</i>	4	-	-	-	-	-	4	-	-	-	-	-
Metabolic	303	(12)	6	149	(17)	7	71	(11)	(3)	83	(4)	14
<i>Avandia products</i>	198	(14)	2	107	(19)	3	46	(18)	(6)	45	2	10
<i>Avandia</i>	121	(19)	(3)	71	(22)	(1)	18	(20)	(10)	32	(12)	(3)
<i>Avandamet</i>	67	(7)	10	29	(8)	16	26	(18)	(7)	12	38	50
<i>Bonviva/Boniva</i>	66	(2)	18	41	(11)	14	23	6	28	2	100	-
Anti-bacterials	381	3	16	46	(8)	18	146	(4)	4	189	12	26
<i>Augmentin</i>	146	2	12	11	13	38	61	-	7	74	3	14
Oncology and emesis	166	19	42	88	19	54	50	12	22	28	32	47
<i>Hycamtin</i>	43	3	23	24	5	26	15	17	25	4	(50)	-
<i>Promacta</i>	3	-	-	3	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	41	64	86	17	18	55	18	88	>100	6	>100	100
<i>Zofran</i>	30	(16)	(3)	4	(25)	-	14	(25)	(13)	12	-	9
Vaccines	756	14	31	196	22	58	320	7	16	240	20	36
<i>Boostrix</i>	39	78	>100	21	78	>100	10	14	43	8	>100	>100
<i>Cervarix</i>	73	>100	>100	-	-	-	63	>100	>100	10	100	>100
<i>Fluarix, FluLaval</i>	14	>100	>100	3	-	-	-	-	-	11	83	83
<i>Flu Pre-Pandemic</i>	30	(26)	(12)	25	-	-	5	(86)	(86)	-	-	-
<i>Hepatitis</i>	195	(2)	17	87	2	32	72	(8)	-	36	7	24
<i>Infanrix, Pediarix</i>	154	(20)	(8)	38	(43)	(22)	91	(13)	(3)	25	(4)	4
<i>Rotarix</i>	71	69	>100	22	-	-	12	20	20	37	20	48
<i>Synflorix</i>	12	-	-	-	-	-	10	-	-	2	-	-
Other	261	(1)	13	2	>100	>100	84	-	5	175	(4)	17
	5,582	(4)	13	2,304	(15)	8	1,746	1	9	1,532	10	28

Pharmaceutical turnover includes co-promotion income

Consumer Healthcare turnover

Three months ended 30th June 2009

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Over-the-counter	573	13	29	183	1	28	185	31	38	205	8	23
<i>alli</i>	82	>100	>100	25	12	47	56	-	-	1	-	-
<i>Breathe Right</i>	20	(6)	11	10	(20)	-	5	-	-	5	33	67
Cold sore franchise	20	(11)	5	9	(22)	-	8	-	>100	3	-	>100
Nicotene replacement	88	12	35	68	13	45	15	8	15	5	20	-
<i>Panadol</i>	94	8	21	-	-	-	20	11	11	74	7	23
<i>Tums</i>	25	(5)	14	22	(5)	16	-	-	-	3	-	-
Oral healthcare	366	7	33	71	10	42	190	4	12	105	13	33
<i>Aquafresh</i> franchise	121	(1)	13	21	(6)	17	71	(2)	8	29	(4)	26
<i>Biotene</i>	6	-	-	5	-	-	1	-	-	-	-	-
Denture care	84	9	27	20	-	33	32	7	19	32	17	33
<i>Sensodyne</i> franchise	113	14	30	23	20	53	50	7	16	40	21	38
Nutritional healthcare	226	2	8	-	-	-	130	(5)	(3)	96	14	26
<i>Horlicks</i>	61	17	27	-	-	-	4	(20)	(20)	57	21	33
<i>Lucozade</i>	106	(4)	(1)	-	-	-	92	(5)	(3)	14	8	17
<i>Ribena</i>	44	(2)	2	-	-	-	33	(6)	(3)	11	11	22
	1,165	9	23	254	3	32	505	10	16	406	11	26

Income statement

Six months ended 30th June 2009

	Total H1 2009 £m	Total H1 2008 £m	Growth	
			CER%	£%
TURNOVER	13,516	11,560	(3)	17
Cost of sales	(3,479)	(2,872)	8	21
Gross profit	10,037	8,688	(7)	16
Selling, general and administration	(4,492)	(3,541)	3	27
Research and development	(2,097)	(1,600)	12	31
Other operating income	459	355		
OPERATING PROFIT	3,907	3,902	(19)	5
Finance income	46	178		
Finance expense	(371)	(384)		
Profit on disposal of interest in associate	115	-		
Share of after tax profits of associates and joint ventures	31	14		
PROFIT BEFORE TAXATION	3,728	3,710	(23)	-
Taxation	(1,098)	(1,071)		
<i>Tax rate %</i>	29.5%	28.9%		
PROFIT AFTER TAXATION FOR THE PERIOD	2,630	2,639	(24)	-
Profit attributable to minority interests	64	46		
Profit attributable to shareholders	2,566	2,593		
	2,630	2,639		
EARNINGS PER SHARE	50.6p	49.0p	(21)	3
Diluted earnings per share	50.3p	48.7p		

Pharmaceuticals turnover

Six months ended 30th June 2009

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	3,469	4	27	1,669	2	35	1,096	-	11	704	13	35
<i>Avamys/Veramyst</i>	78	>100	>100	38	12	46	25	>100	>100	15	>100	>100
<i>Flixonase/Flonase</i>	108	(23)	(3)	18	(62)	(51)	24	(24)	(17)	66	11	47
<i>Flixotide/Flovent</i>	384	(3)	20	196	3	37	91	(3)	5	97	(11)	8
<i>Seretide/Advair</i>	2,459	4	28	1,301	1	34	795	2	13	363	27	48
<i>Serevent</i>	121	(23)	(9)	37	(15)	12	60	(20)	(15)	24	(38)	(17)
<i>Ventolin</i>	228	23	45	70	>100	>100	73	-	11	85	(4)	10
<i>Zyrtec</i>	35	32	84	-	-	-	-	-	-	35	32	84
Anti-virals	2,068	11	39	984	6	40	576	21	35	508	10	41
HIV	801	(9)	11	359	(8)	22	325	(12)	1	117	(6)	13
<i>Agenerase, Lexiva</i>	91	(1)	25	50	6	39	33	(10)	6	8	-	33
<i>Combivir</i>	214	(17)	2	97	(15)	13	78	(21)	(9)	39	(11)	5
<i>Epivir</i>	65	(22)	(4)	24	(18)	9	26	(27)	(13)	15	(19)	(6)
<i>Epzicom/Kivexa</i>	266	8	31	108	3	37	121	5	19	37	41	68
<i>Trizivir</i>	104	(19)	-	55	(18)	10	44	(21)	(8)	5	(17)	(17)
<i>Ziagen</i>	52	(18)	2	25	(10)	19	18	(16)	(5)	9	(36)	(18)
<i>Valtrex</i>	723	6	37	548	12	49	81	(1)	14	94	(16)	8
<i>Relenza</i>	282	>100	>100	30	>100	>100	135	>100	>100	117	>100	>100
<i>Zeffix</i>	108	(9)	16	9	(14)	29	15	-	15	84	(10)	15
Central nervous system	948	(53)	(42)	358	(76)	(69)	289	(5)	6	301	1	29
<i>Imigran/Imitrex</i>	132	(67)	(61)	61	(81)	(78)	48	(9)	2	23	-	28
<i>Lamictal</i>	247	(67)	(60)	131	(81)	(74)	77	(3)	8	39	(3)	15
<i>Requip</i>	101	(43)	(34)	14	(87)	(82)	67	-	12	20	14	43
<i>Requip XL</i>	52	>100	>100	13	-	-	39	>100	>100	-	-	-
<i>Seroxat/Paxil</i>	264	(17)	6	27	(51)	(43)	55	(17)	(7)	182	(6)	28
<i>Treximet</i>	26	>100	>100	26	>100	>100	-	-	-	-	-	-
<i>Wellbutrin, Wellbutrin XL</i>	94	(67)	(58)	74	(73)	(65)	13	83	>100	7	-	-
Cardiovascular and urogenital	1,131	8	36	704	10	46	286	2	16	141	14	36
<i>Arixtra</i>	120	34	69	66	43	89	45	26	45	9	20	80
<i>Avodart</i>	256	16	45	156	13	50	73	14	30	27	47	59
<i>Coreg, Coreg CR</i>	102	(16)	11	101	(15)	11	-	-	-	1	(100)	-
<i>Fraxiparine</i>	113	(8)	4	-	-	-	86	(13)	(1)	27	9	23
<i>Levitra</i>	38	7	41	36	4	38	2	100	100	-	-	-
<i>Lovaza</i>	210	36	79	209	36	80	-	-	-	1	-	-
<i>Vesicare</i>	50	27	67	50	27	67	-	-	-	-	-	-
<i>Volibris</i>	6	-	-	-	-	-	6	-	-	-	-	-
Metabolic	597	(14)	7	299	(17)	10	139	(16)	(5)	159	(6)	14
<i>Avandia products</i>	395	(17)	3	219	(19)	8	89	(24)	(14)	87	(3)	10
<i>Avandia</i>	242	(21)	(2)	145	(24)	1	36	(24)	(14)	61	(13)	(2)
<i>Avandamet</i>	133	(11)	8	60	(6)	22	50	(25)	(15)	23	27	53
<i>Bonviva/Boniva</i>	128	(3)	22	79	(13)	14	44	12	33	5	67	67
Anti-bacterials	807	1	17	93	(17)	11	335	(5)	6	379	12	29
<i>Augmentin</i>	332	1	16	27	(16)	8	145	(5)	7	160	11	28
Oncology and emesis	310	10	35	158	3	37	101	14	29	51	22	38
<i>Hycamtin</i>	86	6	32	50	6	39	30	13	30	6	(17)	-
<i>Promacta</i>	5	-	-	5	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	75	54	83	28	-	33	35	100	>100	12	>100	>100
<i>Zofran</i>	62	(12)	3	11	14	57	28	(25)	(13)	23	-	10
Vaccines	1,381	16	36	315	2	35	606	13	27	460	31	51
<i>Boostrix</i>	65	71	>100	32	71	>100	18	25	50	15	>100	>100
<i>Cervarix</i>	121	>100	>100	-	-	-	102	>100	>100	19	>100	>100
<i>Fluarix, FluLaval</i>	20	>100	>100	3	-	-	-	-	-	17	>100	>100
<i>Flu Pre-Pandemic</i>	36	(21)	(8)	25	-	-	10	(74)	(74)	1	-	-
<i>Hepatitis</i>	344	(7)	12	139	(12)	17	133	(7)	4	72	5	22
<i>Infanrix, Pediarix</i>	329	(13)	3	77	(42)	(23)	200	(1)	14	52	4	16
<i>Rotarix</i>	128	71	>100	37	-	-	25	21	32	66	28	53
<i>Synflorix</i>	12	-	-	-	-	-	10	-	-	2	-	-
Other	494	(14)	-	7	80	40	158	(3)	5	329	(20)	(2)
	11,205	(5)	16	4,587	(19)	7	3,586	4	16	3,032	8	30

Pharmaceutical turnover includes co-promotion income

Consumer Healthcare turnover

Six months ended 30th June 2009

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Over-the-counter	1,140	9	30	363	2	35	341	14	23	436	11	31
<i>alli</i>	114	>100	>100	54	60	>100	59	-	-	1	(50)	(50)
<i>Breathe Right</i>	47	9	34	24	(5)	26	12	10	20	11	50	83
Cold sore franchise	43	(8)	10	18	(13)	13	19	(5)	-	6	-	50
Nicotene replacement	170	12	38	126	12	48	32	7	10	12	33	33
<i>Panadol</i>	193	7	22	-	-	-	40	-	8	153	9	26
<i>Tums</i>	55	-	28	49	-	32	-	-	-	6	-	-
Oral healthcare	734	6	25	149	12	49	374	3	14	211	10	33
<i>Aquafresh</i> franchise	249	-	16	48	(5)	26	144	(2)	11	57	7	24
<i>Biotene</i>	12	-	-	10	-	-	1	-	-	1	-	-
Denture care	164	7	30	39	-	34	60	4	18	65	15	41
<i>Sensodyne</i> franchise	225	10	30	49	23	63	97	5	15	79	12	34
Nutritional healthcare	437	1	8	-	-	-	225	(9)	(8)	212	18	33
<i>Horlicks</i>	136	18	31	-	-	-	9	(18)	(18)	127	23	37
<i>Lucozade</i>	186	(7)	(4)	-	-	-	157	(10)	(8)	29	14	32
<i>Ribena</i>	82	(4)	3	-	-	-	58	(7)	(5)	24	5	26
	2,311	7	24	512	5	39	940	3	11	859	12	32